Metis TechBio Co., Ltd. Class H
1.21
EUR
- -
- -
ISIN
CNE100007LD1
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Tsai-Ta Lai
- Full Time Employees
- 150
- Sector
- Process industries
- Industry
- Chemicals: major diversified
- Address
- Room 201, 2/F, Building 13 Beijing BJ China 102600
- IPO Date
- May 13, 2026
- Website
- metistechbio.com
- Similar Companies
- Business
- Metis TechBio Co., Ltd. operates as an AI-enhanced nanomaterials company focused on delivery technologies for active biological payloads across multiple organ systems, with emphasis on lipid nanoparticle–based delivery platforms and AI-enabled design and screening capabilities; it develops and commercializes a lipid library and de novo lipid language models, AI-driven screening platforms, and multiscale simulation tools to enable targeted therapeutic formulations across humans and animals, serving pharmaceutical, biotechnology, and medical research customers. Founding year and headquarters - Founded in 2020; headquartered in Beijing, China Primary business activity and core offerings - Core products and services: AI-powered nanodelivery platforms for biologics and small molecules; lipid nanoparticle (LNP) libraries and generation pipelines; de novo lipid design models and generative algorithms; AI+multiscale simulations for formulation development; end-to-end LNP screening and optimization platforms; contract research collaborations for mRNA and lipid nanoparticle technologies; animal health product concepts and development pipelines; data-driven screening and design services; collaboration-based licensing and technology integration offerings - Product categories and types: AI-driven nanodelivery platforms; lipid libraries containing millions of lipid structures; generative lipid design models; AI-enhanced molecular simulation suites; high-throughput LNP formulation screening tools; collaboration-based research services; potential asset programs in pet health (e.g., obesity and muscle-targeting therapies) Geographic operations and markets - Operates with a focus on China (Beijing) and United States research and development activities; engages global pharmaceutical, biotechnology, and medical research customers; pursues collaborations and partnerships with international biopharma and listed entities Recent major changes and developments - Strategic partnerships and collaborations: signs multiple research collaboration agreements with US and Chinese partners since mid-2025, including agreements targeting mRNA/LNP technologies and other lipid-based therapeutics; collaboration counts have increased with contract values disclosed per target, signaling expanding external R&D partnerships - Capital market and listing progress: progresses toward listing with emphasis on AI-driven nanodelivery, potentially widening investor access and strategic options; continues to pursue capital market milestones as a growth-focused biotechnology innovator - Product and platform expansions: advances in AI-based lipid design and multiscale simulation for rapid formulation development; expansion of animal health asset programs (PTS-101 for pet obesity and PTS-201 for muscle-targeting therapies) and cross-industry applications beyond therapeutics - Operational and organizational moves: ongoing commercialization and research efforts across multi-region collaborations; expansion of research capabilities and pipeline through new alliances and technology licenses Industry context and positioning - Industry: Biotechnology and pharmaceutical nanomedicine; focus on AI-enabled delivery systems and lipid-based formulations - Business segments: AI biology platforms; lipid nanoparticle development and screening services; contract research collaborations; animal health asset development - Target customers: Pharmaceutical and biotechnology companies, medical research institutions, and partner organizations seeking advanced delivery technologies and rapid formulation development - Subsidiaries/ownership: corporate entity with parent/affiliate relationships in related technology and research collaborations; structure supports multi-jurisdictional research and development activities Notes - The information reflects publicly reported developments and strategic activities through 2025 and into 2026, with emphasis on the company’s core technology platform, product families, and recent collaboration activity.